Showing results (371-380 of 392) with videos related to
Sort By:
Pageof 40
Plos One|November 19, 2010
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateJeffrey R Currier, Viseth Ngauy, Mark S de Souza, et al.Journal of Virology|July 29, 2016
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus MacaquesSmita S Iyer, Sailaja Gangadhara, Blandine Victor, et al.Science (New York, N.Y.)|October 21, 2020
Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivityLudovico Cantuti-Castelvetri, Ravi Ojha, Liliana D Pedro, et al.Journal of Virology|October 8, 2020
Rectal Acquisition of Simian Immunodeficiency Virus (SIV) SIVmac239 Infection despite Vaccine-Induced Immune Responses against the Entire SIV ProteomeMauricio A Martins, Lucas Gonzalez-Nieto, Michael J Ricciardi, et al.Vaccine|January 12, 2012
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challengeJosephine H Cox, Maria G Ferrari, Patricia Earl, et al.The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.Nature|March 12, 2004
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypoxPatricia L Earl, Jeffrey L Americo, Linda S Wyatt, et al.The Journal of Infectious Diseases|October 11, 2003
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaquesYvette Edghill-Smith, David Venzon, Tatiana Karpova, et al.Science Translational Medicine|March 27, 2024
Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaquesCatherine Jacob-Dolan, Darren Ty, David Hope, et al.The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.Pageof 40